Scholarlink

Introduction <p>The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy.</p> Methods <p>This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed.</p> Results <p>Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5&#xa0;days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37&#xa0;weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r.</p> Conclusion <p>Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy

  • 期刊论文

  • 发表日期：

    2025年4月26日

查看全文
  • Hannah Yang,
  • Yosra Elsayed,
  • Victoria Zablocki,
  • Beth Bailey

摘要

Introduction

The aim of this pilot study was to examine, using observational data, birth outcomes following the use of antiviral therapy in pregnancy.

Methods

This retrospective chart review study involved patients diagnosed with COVID-19 who received care at a single university-affiliated obstetrics practice grouped as having received, or not received, Ritonavir-Boosted Nirmatrelvir (NMV-r). Participant background information and birth outcomes were extracted and analyzed.

Results

Of 141 patients, nine were prescribed and took a course of NMV-r. Infants born to patients who were pregnantand took NMV-r had significantly shorter hospital stays (average of 2.5 days less) compared to infants born to patients who did not take NMV-r. In addition, there were multiple non-significant but clinically meaningful group differences: more than 10% of those who did not take NMV-r delivered preterm, while all those who took NMV-r delivered after 37 weeks, and infants born to those who did not take NMV-r were three times more likely to be admitted to the NICU compared to infants born to those who took a course of NMV-r.

Conclusion

Patients who are pregnant andtake NMV-r as treatment for COVID-19 appear to have better birth outcomes than those who do not, with no identified adverse effects in this small convenience sample. Based on this pilot study, NMV-r may improve clinical outcomes for obstetrics patients who contract COVID-19 during pregnancy.